ADICON
艾 迪 康

2026 1H Interim Results

Adicon Holdings Limited

August 25, 2026

Disclaimer

By attending the meeting where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations:

These materials have been prepared by ADICON Holdings Limited (the "Company", and together with its subsidiaries, the "Group") solely for use at this presentation to investors for information purposes only, and have not been independently verified. No representations or warranties, express or implied, are made as to, and no reliance should be placed on, the accuracy, fairness completeness or correctness of the information or opinions presented or contained in these materials. Neither the Company, any member of the Group nor the Joint Sponsors, the Overall Coordinators, the Joint Global Coordinators, the Joint Lead Managers, the Joint Bookrunners, the Capital Market Intermediaries, the Underwriters nor any of their respective affiliates, controlling persons, directors, officers, employees, advisers or representatives shall have any liability whatsoever, as a result of negligence or otherwise, for any loss howsoever arising from any information or opinions presented or contained in these materials. The information or opinions presented or contained in these materials are subject to change without notice, and shall only be considered current as of the date hereof.

These materials contain statements that reflect the Company's beliefs or expectations about the future or future events as of the respective dates indicated therein ("forward-looking statements"). These forward-looking statements are based on a number of assumptions about the Group and other matters, such as the Group's operations, its future development plans, market (financial and otherwise) conditions, growth prospects, and are subject to known and unknown risks, uncertainties and other factors beyond the Group's control, and accordingly, actual results may differ materially from the results expressed or implied by these forward-looking statements. Each of the Company, members of the Group, the Joint Sponsors, the Overall Coordinators, the Joint Global Coordinators, the Joint Lead Managers, the Joint Bookrunners, the Capital Market Intermediaries and the Underwriters undertakes no obligation to update these forward-looking statements for events/or circumstances that occur subsequent to such dates.

These materials do not constitute or form part of and should not be construed as, a prospectus or other offering document or an offer or invitation to acquire, purchase or subscribe for any securities nor are they calculated to invite any such offer or invitation. In particular, these materials do not constitute and are not an offer to sell or a solicitation of any offer to buy securities in Hong Kong, the United States or anywhere else. No part of these materials shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. The securities referred to herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "Securities Act") or securities laws of any state in the United States and may not be offered or sold in the United States without registration under the Securities Act, or except pursuant to an applicable exemption from, or in a transaction not subject to the registration requirements of the Securities Act and securities laws of any state in the United States. In Hong Kong, no securities of the Company may be offered to the public unless a prospectus in connection with the offering for sale or subscription of such securities has been authorized by The Stock Exchange of Hong Kong Limited for registration by the Registrar of Companies of Hong Kong, and has been so duly registered. Otherwise, without due registration, a prospectus must not be distributed, issued or circulated in Hong Kong. The offering circular of the Company in connection with the offering in the United States, Hong Kong or elsewhere will contain detailed information about the Group and its management as well as the financial statements of the Group. Nothing in these materials constitutes or forms any part of an offer of securities for sale in the United States, Hong Kong or any other jurisdiction, nor does it constitute or form any part of an invitation by or on behalf of the Company, any member of the Group or their respective affiliates or the Joint Sponsors, the Overall Coordinators, the Joint Global Coordinators, the Joint Lead Managers, the Joint Bookrunners, the Capital Market Intermediaries or the Underwriters or any of their respective affiliates, advisers or representatives to subscribe for or purchase any securities. Any decision to purchase securities in the offering should be made solely on the basis of the information contained in the offering circular in relation to the offering.

These materials are highly confidential, are being given solely for your information. The information or opinions contained herein and information presented orally or otherwise may not be copied, reproduced, redistributed, or otherwise disclosed, in whole or in part to any other person (whether within or outside your organization/firm) in any manner without the prior written consents of the Company, the Joint Sponsors, the Overall Coordinators, the Joint Global Coordinators, the Joint Lead Managers, the Joint Bookrunners, the Capital Market Intermediaries and the Underwriters. By attending this presentation, you are agreeing to maintain absolute confidentiality regarding this presentation and the information disclosed in these materials or presented orally or otherwise.

Neither these materials nor any part or copy of them may be taken or transmitted into or distributed in or into (by mail, facsimile, electronic or computer transmission or by any other means whatsoever), directly or indirectly, the United States (including its territories and possessions, any State of the United States and the District of Columbia). Any failure to comply with these restrictions may constitute a violation of United States securities laws. The distribution of these materials in other jurisdictions may be restricted by law, and persons into whose possession these materials come should inform themselves about, and observe, any such restrictions. The materials are not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident in any jurisdiction where such distribution or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction.

By accepting this document, you are agreeing: (i) that you have read and agree to comply with the contents of this notice; (ii) to maintain absolute confidentiality regarding this presentation and the information disclosed in these materials or presented orally or otherwise; and (iii) you and any persons you represent are either (x) a "qualified institutional buyer" (within the meaning of Rule 144A under the Securities Act) or (y) outside the United States. This document is not intended for distribution to persons who are not professional investors (as defined in Schedule 1 to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

Company Overview

ADICON
艾 迪 康

2026 1H: Operational Inflection Confirmed, with Core Businesses Entering an Accelerated Growth Phase

ADICON 艾迪康

1.285bn	+34.9%	+17.4%	+11.1%	37.9%	51.42mn	184mn
Total Revenue	**CRO Revenue YoY**	**Co-construction Revenue YoY**	**Esoteric Revenue YoY**	**Gross Margin**	**Adjusted Net Profit**	**Adjusted EBITDA**
↑1.1% YoY **Back to Positive Growth**	↑New Contract Value **Strong Growth**	↑New Contract Value **Doubled**	↑Growth Across **Multiple** Service Lines	↑2.1pct **Significant Improvement**	↑19.6% YOY **Back to Positive Growth**	↑11.7% YOY **Back to Positive Growth**

ICL: Esoteric +11% YoY; Co-construction +17% YoY

Esoteric

Overall Performance

+11%	30%	+26%
2026H1 Revenue YoY	2026H1 % of Revenue	2021-2025 CAGR

Strong Growth Across Hematology, Infectious Disease, Maternal and Child Health, Oncology and Reproductive Genetics





Esoteric Revenue up 11% YoY, with Accelerating Growth Momentum



Co-construction

Overall Performance

+17%	14%	+37%
2026H1 Revenue YoY	2026H1 % of Revenue	2022-2025CAGR

Large Contracts Grow; Strategic Partnerships Materialize

- ✓ **2026 H1**: value of new contracts up ***114%*** YoY; revenue nearly ***180 million***, up ***17%*** YoY; revenue from public tertiary hospitals up ***11%*** YoY
- ✓ **Policy Tailwinds:** Accelerated construction of regional medical centers boosts demand
- ✓ **Strategic Upgrade:** Quality projects for scale & value growth

Partnerships

Jointown

Mindray

Capital Medical University

Lin'an District Testing Center

Co-construction Contract Value More Than Doubled and become a Key Revenue Growth Driver



Routine Testing Bottoming Out; CRO Growth Accelerating

CRO (Excluding GH)

Clinical Trials & Approvals → Clinical Diagnostics

2026H1 Revenue YoY
+35%

2026H1 Value of New Contracts
Strong Growth

Strategic Partnership with Gan & Lee

CRO Revenue Trends (Excluding GH)



Routine Testing

Overall Performance

+0.1%
Routine Testing
2026H1
Revenue YoY

Rising Industry Outsourcing and Market Share Gains Accelerated Volume Growth, Offsetting Pricing Pressure

2025H1vs2026H1: Routine Testing Revenue



2026H1 Laboratory Testing Volume Trend



Health Check-up Business (<5% of Revenue)

Health Check-up Revenue Declined: Industry Headwinds and Changes in Customer Mix

2025H1vs2026H1: Health Check-up Revenue



Bidding: Total Successful Bid Value Doubled with Stronger Client Retention

ADICON 艾迪康

Tender Bids in 2026H1

690mn
Successful Bid Amount
+100%YoY

72%
Market Opportunities Coverage Rate
+22%YoY

95.8%
Key Client Retention Rate

Successful Bid Amount



Market Opportunities Pursued



# of Successful Bids in Tier II/III Hospitals



Operational Efficiency: Improved Cost Efficiency and Strengthened Quality Leadership

ADICON 艾迪康

Cost Control

- ↓12% Reagent Procurement Price
- ↓ 9% Logistics Cost per Sample

Efficiency Improvement

- ↑15% Manpower Efficiency

Quality Control

- 25 ISO 15189 Laboratory
- 18 ISO 9001/ 14001/45001
- 467 ISO 15189 Program (Hangzhou)

37.9% Gross Margin ↑ +2.1 pct

4.0% Adjusted Net Margin ↑ +0.6 pct

Ecosystem Development | Co-construction

ADICON 艾迪康

Comprehensive Strategic Agreement with Mindray (300760.SZ)

Date: January 30

Collaboration will span regional testing centers, hospital laboratories and supply-chain resource sharing, promoting advanced medical testing technologies and management models while sharing expert, clinical and academic resources. The two parties will also advance “AI + Diagnostics” innovation and jointly develop customized smart diagnostic solutions and products for hospitals.

Strategic Partnership Established with Jointown (600998.SH)

Date: April 2

The parties established a stable three-year partnership focused on regional testing centers, hospital laboratories and supply-chain resource sharing. Jointown Medical Devices Group’s supply-chain expertise complements ADICON’s medical testing capabilities, marking a key step from resource complementarity to ecosystem co-development.

Strategic Cooperation Framework Agreement with Haier Biomedical (688139.SH)

Date: July 17

The partnership upgrades equipment procurement to end-to-end digital collaboration, creating an integrated digital ecosystem across the full medical testing lifecycle. It will focus on channel collaboration, joint R&D, cold-chain development and standards co-creation, exploring innovative solutions from laboratory development to end-to-end sample management.

—— Co-construction Partnerships ——

Ecosystem Development | AI & Digitalization

ADICON 艾迪康

Partnering with Technology Leaders

Joint Development · Vertical Expertise

ADICON works closely with technology partners, including Huawei and Digital China, to explore multimodal medical foundation models while developing its proprietary domain-specific medical model, “Wenyi.” Trained on ADICON’s extensive clinical sample data, the model has significantly improved efficiency in pathology slide review and flow cytometry analysis.

Co-building Smart Regional Testing Centers

Data Connectivity · Smart Collaboration

ADICON is partnering with the Capital Medical University Clinical Laboratory Center to develop AI-powered regional testing. Leveraging its nationwide logistics network, 4,000+ tests and proprietary “Wenyi” model, ADICON integrates logistics, data and knowledge to enhance testing efficiency, standardization and access to quality medical resources.

Partnering with Leading Healthcare Ecosystems

Explore AI - To - Consumer Opportunities

Seeking deep integration with leading tech firms’ large-health ecosystems. Capitalizing on diagnostic expertise, we expand testing services into diverse wellness scenarios. Underpinned by “licensed ICL + Internet Hospital” for trust and compliance, DTC drives brand, direct user access and data assets; B2B2C generates replicable scalable profits.



—— AI & Digitalization ——

Digital Strategy: Comprehensive Upgrade of Digital Capabilities to Drive Efficiency Gains and Unlock Value

ADICON 艾迪康

Smart Laboratory Testing

LIMS Autoverification

Routine Clinical Testing Items Covered	Assisted Verification Pass Rate (July)	Verification Efficiency
700+	85%	+15%

AI-Assisted Pathology Diagnosis

Cumulative AI-Assisted Slide Reviews (Jan 2023–Jul 2026)	15mn+
Annual Slide Review Volume	4.7mn+
Penetration Rate	89%

AI Quality Control

AI quality control draws on all histopathology case data and performs multidimensional checks to safeguard report quality

Average Monthly Cases	26H1 Abnormal Reports intercepted
126K	8,035

Regional Collaboration

"Single-Barcode" Functionality

Front-End Sample Intake: Client Barcode | Central Lab Barcode

→ Barcode Check

- No Duplicate → Use Client Barcode
- Duplicate → Use ADICON Barcode

Sample Intake Efficiency Improved



Regional LIS

Unified Testing → Unified Quality Control → Mutual Recognition



- ✓ Serving **14** regions
- ✓ Covering **hundreds** of primary healthcare institutions
- ✓ Daily test report volume on a single regional testing center platform can **exceed 3,000**

Data Assets

Accumulated Multimodal, Multi-omics Medical Testing Data: **20PB**

Data Assets

LIMS | PIMS | OMS | NGS | Logistics

→ **20 Years of Data**

Internal BI	External Services
Profit	AI Training
Operations	Insurance
Strategy	Pharma Data
Risks	Collaboration

Smart Diagnostics

For **mid-large hospital clients**, with an emphasis on **diagnostics process management**



For **regional healthcare centers**, assisting to **improve resource allocation**

Platform SaaS for **smaller hospital clients**

Financial Highlights

ADICON
艾 迪 康

Revenue Returns to Growth, Core Financial Metrics Continue to Recover

ADICON 艾迪康

Total Revenues



Gross Profit



Adjusted EBITDA(1)



Adjusted Net Profit(2)



Notes:

1. Adjusted EBITDA is defined as EBITDA (profit before tax plus depreciation and amortization expenses and finance costs, minus bank interest income) plus share-based compensation expenses, listing expenses, fair value loss on financial liabilities at FVTPL, fair value gains on contingent consideration, fair value gains on put option over non-controlling interests, fair value losses/(gains) on derivative financial instruments, fair value losses/(gains) on segregated portfolio, foreign exchange losses/(gains), Covid related inventory impairments, Covid-19 related bad debt impairment, strategic restructuring charges, and M&A related costs.
2. Adjusted net profit is defined as profit for the year adjusted for, net of tax, share-based compensation expenses, listing expenses, fair value loss on financial liabilities at FVTPL, fair value gains on contingent consideration, fair value gains on put option over non-controlling interests, fair value losses/(gains) on derivative financial instruments, fair value losses/(gains) on segregated portfolio, foreign exchange losses/(gains), Covid related inventory impairments, Covid-19 related bad debt impairment, strategic restructuring charges, and M&A related costs.

Optimizing Resource Allocation to Support Sustainable Long-Term Growth

ADICON 艾迪康

Selling and Marketing Expenses



Administrative Expenses[1]



Notes:
1. Administrative expenses, dotted yellow line excluding non-cash ESOP expenses.

Working Capital Remains Stable, with Enhanced Receivables Collection Management

ADICON 艾迪康

Inventory Turnover Days[1]



Trade Receivables Turnover Days[2]



Trade Receivables Turnover Days[3]



Trade Receivable Expected Credit Losses (ECL)[4]



Notes:

1. Average balance of inventory for the year, divided by costs of sales for the same year and multiplied by 365 days.
2. Average trade receivables turnover days using the average balance of trade receivables for the year, divided by revenue for the relevant year, multiplied by 365 days. Pro forma figures breaking our receivables balance from large screenings Covid in light yellow and pro forma receivables days calculated not including large screening Covid receivables.
3. Average balance of trade payables for the year, divided by costs of sales for the relevant year, multiplied by 365 days.
4. The stacked red bar represents the Expected Credit Losses (ECL) beginning balance and pink stacked bar represents the ECL reserves net of write-downs for each year. Note a negative pink stacked bar means we took more write-downs than reserves in that year. The number above each bar represents the % of ECL balance as a percentage of gross trade receivables at the end of each period.

Income Statement

RMB '000	Year ended 31 December							For the 6 months ended 30 June	
	2019	2020	2021	2022	2023	2024	2025	2025H1	2026H1
REVENUE	**1,729,261**	**2,741,731**	**3,379,515**	**4,860,613**	**3,297,828**	**2,914,113**	**2,638,450**	**1,270,559**	**1,284,764**
Cost of sales	-1,208,328	-1,625,071	-1,937,126	-2,964,448	-1,863,721	-1,815,464	-1,685,967	-816,087	-797,624
Gross profit	**520,933**	**1,116,660**	**1,442,389**	**1,896,165**	**1,434,107**	**1,098,649**	**952,483**	**454,472**	**487,140**
Other income and gains	3,421	12,686	14,763	50,811	61,609	49,261	32,326	12,664	17,639
Selling and marketing expenses	-208,216	-359,051	-489,783	-553,272	-485,155	-465,691	-452,850	-196,376	-210,917
Administrative expenses	-116,966	-236,566	-263,003	-282,262	-271,015	-253,274	-248,490	-112,638	-130,194
Research and development costs	-69,932	-102,009	-125,446	-162,746	-143,522	-120,037	-103,674	-54,904	-49,504
Other expenses	-24,260	-37,712	-48,530	-128,440	-99,622	-164,590	-79,325	-35,730	-27,486
Listing expenses	-	-16,179	-35,290	-9,664	-72,189	-	-	-	-
Finance costs	-17,382	-19,644	-16,326	-76,824	-86,316	-52,358	-48,506	-21,980	-23,255
Share of loss of an associate	-	-	-	-	-	-	-180	-	-839
Fair value loss on financial liabilities at FVTPL	-	-	-61,531	87,044	11,475	-	-	-	-
PROFIT BEFORE TAX	**87,598**	**358,185**	**417,243**	**820,812**	**349,372**	**91,960**	**51,784**	**45,508**	**62,584**
Income tax expense	-17,155	-68,732	-94,948	-135,928	-87,050	-29,397	-29,039	-16,939	-27,317
PROFIT FOR THE YEAR	**70,443**	**289,453**	**322,295**	**684,884**	**262,322**	**62,563**	**22,745**	**28,569**	**35,267**
Attributable to:									
Owners of the parent	67,906	284,121	315,540	680,793	234,885	47,014	18,443	27,273	32,006
Non-controlling interests	2,537	5,332	6,755	4,091	27,437	15,549	4,302	1,296	3,261

Adjusted EBITDA – non-IFRS reconciliation

	Year ended 31 December							For the 6 months ended 30 June	
RMB '000	2019	2020	2021	2022	2023	2024	2025	2025H1	2026H1
PROFIT BEFORE TAX	**87,598**	**358,185**	**417,243**	**820,812**	**349,372**	**91,960**	**51,784**	**45,508**	**62,584**
(+) Depreciation	85,736	113,118	136,235	188,565	158,949	166,059	172,659	82,775	85,817
(+) Amortization	610	662	1,617	4,853	8,490	10,034	12,262	5,523	6,511
(+) Finance costs	17,382	19,644	16,326	76,824	86,316	52,358	48,506	21,980	23,255
(-) Bank interest income	889	3,765	6,289	8,874	20,160	21,472	13,185	6,804	6,672
EBITDA	**190,437**	**487,844**	**565,132**	**1,082,180**	**582,967**	**298,939**	**272,026**	**148,982**	**171,495**
(+) 1. Share based compensation expenses	2,735	63,598	37,325	15,049	17,054	2,151	4,943	3,523	-2,084
(+) 2. Listing expenses	-	16,179	35,290	9,664	72,189	-	-	-	-
(+) 3. FV loss/(gain) on financial instruments at FVTPL	-	-	61,531	-87,044	-11,475	-	-	-	526
(+) 4. FV gains on contingent consideration	-	-	-	-13,337	-	-	-	-	-
(+) 5. FV gains on put option over non-controlling interests	-	-	-	-	-15,305	-	-	-	-
(+) 6. FV losses/(gains) on derivative financial instruments	-	-	-	-7,826	6,165	4,486	-344	-	-
(+) 7. FV losses/(gains) on segregated portfolio	-	-	-	-	-	-2,256	-	-	-
(+) 8. Foreign exchange (gains)/losses, net	434	-1,427	50	6,743	8,198	-7,594	19,518	5,335	2,714
(+) 9. Covid-19 related inventory impairment	-	-	-	1,421	15,976	2,320	-	-	-
(+) 10. Covid-19 related bad debt impairment	-	-	-	-	-	98,671	-	-	-
(+) 11. Strategic restructuring charges	-	-	-	-	-	25,590	18,599	6,536	8,854
(+) 12. M&A Related Costs	-	-	-	-	-	-	2,123	-	2,178
ADJUSTED EBITDA	**193,606**	**566,194**	**699,328**	**1,006,850**	**675,769**	**422,307**	**316,864**	**164,376**	**183,684**
yoy growth	81.40%	192.40%	23.50%	44.00%	-32.90%	*-37.50%*	*-24.97%*	-30.9%	11.7%
Adjusted EBITDA margin	11.20%	20.70%	20.70%	20.70%	20.50%	*14.50%*	*12.01%*	12.9%	14.3%

Adjusted Net Income – non-IFRS reconciliation

	Year ended 31 December							For the 6 months ended 30 June	
RMB '000	2019	2020	2021	2022	2023	2024	2025	2025H1	2026H1
PROFIT FOR THE YEAR	**70,443**	**289,453**	**322,295**	**684,884**	**262,322**	**62,563**	**22,745**	**28,569**	**35,267**
(+) Share based compensation expenses	2,735	63,598	37,325	15,049	17,054	2,151	4,815	3,423	-2,089
(+) Listing expenses	-	13,984	30,087	8,204	72,099	-	-	-	-
(+) FV loss/(gain) on financial instruments at FVTPL	-	-	61,531	-87,044	-11,475	-	-	-	-
(+) FV gains on contingent consideration	-	-	-	-13,337	-	-	-	-	-
(+) FV gains on put option over non-controlling interests	-	-	-	-	-15,305	-	-	-	-
(+) FV losses/(gains) on derivative financial instruments	-	-	-	-7,826	6,165	4,486	-344	-	-
(+) FV losses/(gains) on segregated portfolio	-	-	-	-	-	-2,256	-	-	-
(+) Foreign exchange (gains)/losses, net	434	-1,427	50	6,743	8,198	-7,594	19,519	5,222	2,714
(+) Covid-19 related Inventory Impairment	-	-	-	1,421	15,976	2,415	-	-	-
(+) Covid-19 related bad debt impairment	-	-	-	-	-	77,272	-	-	-
(+) Strategic restructuring charges	-	-	-	-	-	23,692	17,217	5,793	7,758
(+) M&A Related Costs	-	-	-	-	-	-	2,123	-	2,178
(+) Prior periods tax benefit losses	-	-	-	-	-	-	-	-	5,588
ADJUSTED NET INCOME	**73,612**	**365,608**	**451,288**	**608,094**	**355,034**	**162,729**	**66,074**	**43,007**	**51,416**
yoy growth	2201.10%	396.70%	23.40%	34.70%	-41.60%	*-54.20%*	-59.40%	-60.2%	19.6%
Adjusted Net Income margin	4.30%	13.30%	13.40%	12.50%	10.80%	*5.60%*	2.50%	3.4%	4.0%

Balance Sheet

RMB '000	As of 31 December 2021	2022	2023	2024	2025	As at 30 June 6/30/2026
NON-CURRENT ASSETS						
Property and equipment	266,137	375,428	410,987	398,520	373,427	359,434
Right-of-use assets	173,381	218,853	187,390	165,719	165,684	161,115
Deferred tax assets	74,560	118,403	103,971	129,180	133,637	130,235
Other intangible assets	20,504	143,709	151,416	154,064	179,047	176,633
Prepayments, deposits and other receivables	9,645	12,839	12,575	54,543	40,139	58,518
Investments in an associate	-	-	-	-	6,653	5,814
Amounts due from related parties	1,816	2,123	2,474	2,511	2,555	2,506
Goodwill	25,691	79,802	79,802	79,802	117,214	117,214
Financial assets at fair value through profit or loss	-	8,104	1,535	-	79,774	78,768
Pledged deposits	-	-	300,000	650,000	694,000	694,000
Total non-current assets	**571,734**	**959,261**	**1,250,150**	**1,634,339**	**1,792,130**	**1,784,237**
CURRENT ASSETS						
Inventories	109,395	229,413	176,593	126,935	129,279	109,939
Trade and bills receivables	1,213,512	1,856,847	1,515,434	1,377,364	1,298,934	1,429,487
Financial assets at FVTPL	-	-	50,837	-	4,551	5,031
Prepayments, deposits and other receivables	105,716	127,860	188,474	196,521	210,053	223,271
Amounts due from related parties	270	227	25	25	27,264	37,404
Cash and cash balances	1,109,211	1,680,625	959,423	1,043,833	1,103,174	870,903
Pledged deposits	-	-	412,602	306,000	238,200	192,515
Total current assets	**2,538,104**	**3,894,972**	**3,303,388**	**3,050,678**	**3,011,455**	**2,868,550**
CURRENT LIABILITIES						
Trade and bills payables	510,691	1,062,452	742,108	721,814	696,965	629,963
Other payables and accruals	689,136	985,104	755,527	613,380	525,808	468,725
Contract liabilities	20,683	21,060	34,664	29,905	23,397	15,050

RMB '000	As of 31 December 2021	2022	2023	2024	2025	As at 30 June 6/30/2026
Interest-bearing bank borrowings	49,141	112,792	95,870	467,975	763,933	695,712
Profit tax payable	50,303	124,553	77,790	30,274	21,039	18,994
Amounts due to related parties	36,167	61,071	1,858	1,081	6,972	8,963
Lease liabilities	31,653	51,400	49,201	60,709	58,855	46,237
Total current liabilities	**1,387,774**	**2,418,432**	**1,757,018**	**1,925,138**	**2,096,969**	**1,883,644**
Net Current Assets	**1,150,330**	**1,476,540**	**1,546,370**	**1,125,540**	**914,486**	**984,906**
Total Assets Less Current Liabilities	**1,722,064**	**2,435,801**	**2,796,520**	**2,759,879**	**2,706,616**	**2,769,143**
NON-CURRENT LIABILITIES						
Interest-bearing bank borrowings	90,790	1,023,329	791,647	837,943	704,722	752,700
Lease liabilities	146,297	182,455	153,117	124,523	123,304	120,567
Deferred tax liabilities	10,260	28,502	23,166	22,737	25,326	22,990
Convertible redeemable preferred shares	621,870	589,179	-	-	-	-
Other non-current liabilities	-	-	-	-	4,000	-
Total non-current liabilities	**869,217**	**1,823,465**	**967,930**	**985,203**	**857,352**	896,257
Net Assets	**852,847**	**612,336**	**1,828,590**	**1,774,676**	**1,849,264**	**1,872,886**
EQUITY						
Share capital	86	86	97	97	97	97
Treasury Shares	-	-	-	-112,120	-61,079	-59,166
Reserves	804,155	510,738	1,707,974	1,760,108	1,781,576	1,804,924
Non-controlling interests	48,606	101,512	120,519	126,591	128,670	127,031
Total equity	**852,847**	**612,336**	**1,828,590**	**1,774,676**	**1,849,264**	**1,872,886**
Total Cash (incl pledged deposits)	**1,109,211**	**1,680,625**	**1,672,025**	**1,999,833**	**2,035,374**	**1,757,418**
Net Cash (incl pledged deposits)	**969,280**	**544,504**	**784,508**	**693,915**	**566,719**	**309,006**

ADICON
艾 迪 康

THANK YOU